EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model
about
Aptamer-Mediated Targeted Delivery of Therapeutics: An UpdateSimultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells.Cell-targeting aptamers act as intracellular delivery vehicles.Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancerTrends in the Design and Development of Specific Aptamers Against Peptides and Proteins.Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.Aptamer selection and applications for breast cancer diagnostics and therapy.Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells.Current Advances in Aptamers for Cancer Diagnosis and Therapy.Inhibitors of apoptosis: clinical implications in cancer.Multivalent Aptamer-RNA Conjugates for Simple and Efficient Delivery of Doxorubicin/siRNA into Multidrug-Resistant Cells.Targeted silencing of Survivin in cancer cells by siRNA loaded chitosan magnetic nanoparticles.Iron-dependent cell death as executioner of cancer stem cells.Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.Five-Part Pentameric Nanocomplex Shows Improved Efficacy of Doxorubicin in CD44+ Cancer Cells.Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth
P2860
Q28066827-A1FEA259-5787-4129-B552-B99730D257C3Q33588273-902C221E-5CF5-4E45-BBA8-46E56622FA89Q33919094-579AF710-1970-4C78-AD7D-05A1BF8F843AQ36062913-54425D66-1A5F-4048-B1A2-B66433328D01Q37125328-0778CB62-AD08-4748-A50E-068446FEFB4FQ38777639-699AC056-352F-4EBA-92FA-757351067F92Q38937280-C49FE1B6-F2F7-4709-8206-545A150C8542Q42317503-037144B6-554F-45E5-A0CE-D75AEDAF4C4CQ47097941-FC326C97-618A-41D0-9A97-81A59476E3B3Q47108689-814A835B-6DEE-43EA-BD82-8102767F3A39Q47168257-04445BFD-10E7-4FC0-9904-3A8F479772F3Q47561686-0A3036C4-A452-42FE-87C6-8E512C68DFC8Q47607136-64EAB471-9617-4549-B59E-77743112171CQ51318036-6CF2E680-5B07-4807-A397-BF9D4E4E56B3Q53111022-ED9B2344-9147-4191-B0CA-5D11F171800CQ54936964-DF4AB463-63D2-4C55-ACD2-78B3CCA2BC92Q55036897-7DA2E658-C821-4948-8F77-694E2F053FDEQ55657196-11ECEB75-9D82-4974-80B8-FA19F24F2B97Q58728275-91315670-ADC8-4D8D-83F8-070202975AD8
P2860
EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
EpCAM Aptamer-mediated Survivi ...... bicin in a Breast Cancer Model
@ast
EpCAM Aptamer-mediated Survivi ...... bicin in a Breast Cancer Model
@en
type
label
EpCAM Aptamer-mediated Survivi ...... bicin in a Breast Cancer Model
@ast
EpCAM Aptamer-mediated Survivi ...... bicin in a Breast Cancer Model
@en
prefLabel
EpCAM Aptamer-mediated Survivi ...... bicin in a Breast Cancer Model
@ast
EpCAM Aptamer-mediated Survivi ...... bicin in a Breast Cancer Model
@en
P2093
P2860
P50
P356
P1433
P1476
EpCAM Aptamer-mediated Survivi ...... bicin in a Breast Cancer Model
@en
P2093
Andrew G Bean
Dongxi Xiang
Hadi AlShamaileh
Lijue Chen
Matthew Bruce
Ming Q Wei
Sarah Shigdar
Shu-Feng Zhou
P2860
P304
P356
10.7150/THNO.11692
P577
2015-10-20T00:00:00Z